Wouter Meuleman

Board Observer

2022 - Current

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be learned from a simple blood draw. By understanding the fundamental biology behind disease at any given moment, researchers and clinicians can better target medicines to the right patients in both drug development and clinical practice. Precede seeks to improve success rates for developers of new medicines and to be a part of building a future where every patient can receive a rapid, minimally invasive diagnosis and therapy that is precise to the biology of their disease.

Partner

2020

Illumina Ventures pursues investments in early stage companies that are pioneering new applications of nucleic acid sequencing, developing products that will expand the genomics ecosystem, and utilizing genomics to improve human health.

Principal

2016 - 2020

Board Member

2021

RedShiftBio has developed a proprietary life sciences platform combining its Microfluidic Modulation Spectroscopy (MMS) and expertise in high powered quantum cascade lasers that provides ultra-sensitive and ultra-precise measurements of molecular structure.

Board Member

2021

Lightcast Discovery is developing a flexible, accessible platform to accelerate single-cell, functional analysis at scale. Consolidating multiple, complex assays into intuitive streamlined workflows, the company is addressing key limitations in existing methods to provide the freedom to innovate and discover across a broad range of disciplines, from basic and translational research to drug discovery.

Board Member

2019

Fluent BioSciences, develops high sensitivity molecular analytical products that enables usage of extremely low molecular and cellular sample inputs.

Board Observer

2018

Ribometrix is a platform therapeutics company discovering small-molecule drugs that target functional RNA structures to create new avenues to treat human disease.

Board Observer

2019

Board Member

2015

Biota applies DNA sequencing and data science to explore the earth's subsurface. It offers DNA data services for production profiling, sweet spot identification, and reservoir connectivity.

Board Observer

2017

DNA Script is focused on the manufacturing of synthetic DNA using a proprietary template-free enzymatic technology. This technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemical production, improved crops as well as new applications such as data storage.

Director, Corporate and Business Development

2015 - 2019

Illumina, Inc. is a Life Sciences tools company developing, manufacturing and marketing integrated systems for the analysis of genetic variation and biological function.

Principal Scientist

2011 - 2014

Senior Staff Scientist

2010 - 2011

Staff Scientist

2009 - 2010